Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 USD | -3.88% | -6.80% | -12.74% |
06-12 | CSPC Pharmaceutical Buys Back Further Shares | MT |
06-11 | CSPC Pharmaceutical Repurchases 7 Million Shares | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 10.72 for the current year and 9.99 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.74% | 9.77B | - | ||
+51.99% | 798B | C+ | ||
-5.72% | 356B | C+ | ||
+18.94% | 328B | B- | ||
+11.07% | 304B | C+ | ||
+16.96% | 244B | B+ | ||
+2.25% | 227B | A+ | ||
+11.15% | 216B | B- | ||
+7.59% | 166B | C+ | ||
-3.65% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1093 Stock
- CSPCY Stock
- Ratings CSPC Pharmaceutical Group Limited